Market Intelligence, Clinical Progress, and High-Purity Reagents for Iron Homeostasis Disorders.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for SLC40A1 (Ferroportin-1) drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Gene Delivery | SLC40A1 Full-Length ORF Lentivirus (High titer >10^8 TU/mL, Puromycin selectable. Native folding preserved for stable cell line generation.) | View SLC40A1 Products |
| Antigen (Loops) | SLC40A1 Extracellular Loop Peptides (>95% purity, Sequence Verified, Endotoxin Controlled for antibody panning.) | View SLC40A1 Products |
| Disease Variants | SLC40A1 Hemochromatosis Mutant Panel (Y333H, N144H, A77D, C326Y, V162del) – Type 4 HH-associated variants. Sequence Verified. | View SLC40A1 Products |
| Benchmark Ab | Anti-SLC40A1 Neutralizing Antibody (Clone FPN-1) – Recombinant positive control for iron export inhibition and functional comparison. | View SLC40A1 Products |
| Validator | SLC40A1 siRNA Set – For knockdown verification and specificity controls. | View SLC40A1 Products |
| Related Target A | HAMP (Hepcidin) – Endogenous ligand regulating FPN1 degradation. | View HAMP Products |
| Related Target B | TFRC (Transferrin Receptor 1) – Synergistic target in systemic iron homeostasis. | View TFRC Products |
| Related Target C | TMPRSS6 (Matriptase-2) – Negative regulator of hepcidin expression, upstream node in iron regulation. | View TMPRSS6 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Complex 12-TM Membrane Topology & Preservation | Full-Length Lentiviral Expression in HEK293 – Native membrane insertion verified by Flow Cytometry. |
| Lack of Extracellular Epitopes / Functional Iron Export Validation | Sequence-verified extracellular loop peptides (>95% purity) for antibody generation; Stable cell lines with iron-efflux capacity (Calcein-AM or Radioiron compatible). |
| Hepcidin Resistance Mutations (Type 4 HH) | Hemochromatosis Variant Panel (Y333H, C326Y, N144H, A77D, V162del) for resistance screening and selectivity testing. |
| Cross-species Preclinical Translation | Human/Mouse/Cyno FPN ortholog stable cell lines (>95% sequence homology) for PK/PD cross-reactivity studies. |
| Mechanistic Differentiation (Block vs Degrade) | Internalization Assay Ready: High-surface expression clones for antibody-induced uptake studies (Flow Cytometry compatible). |
Live SLC40A1/FPN1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- View Active Clinical Trials
- Latest Resistance Research (Hemochromatosis Mutations)
- Recent Patent Filings
Global Clinical Landscape & Future Outlook
The race for SLC40A1/FPN1 therapeutics is shifting from traditional chelation therapy toward precision modulation of iron export. As first-generation anti-FPN antibodies, hepcidin mimetics, and small molecule inhibitors enter Phase II for hereditary hemochromatosis, thalassemia, and anemia of inflammation, the next wave of R&D focuses on overcoming genetic resistance mutations (e.g., Y333H, N144H, A77D leading to hepcidin insensitivity), achieving tissue-specific iron redistribution (macrophage vs hepatocyte), and developing subcutaneous high-concentration formulations. Major players include Vifor Pharma, Eli Lilly, Protagonist Therapeutics, Disc Medicine, and Ionis Pharmaceuticals.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecules | Vifor Pharma, Disc Medicine, Forma Therapeutics | Beta-thalassemia, Polycythemia Vera, Iron Overload | Cell-based Iron Efflux Assay (stable cell lines via Lentivirus); Mutant vs WT selectivity panel. |
| Monoclonal Antibodies | Eli Lilly, Vifor Pharma | Anemia of Chronic Disease, Type 4 Hemochromatosis | Hepcidin Blockade Validation (high-purity loop peptides); Internalization assay for block vs degrade differentiation. |
| Hepcidin Mimetics | Protagonist Therapeutics, Merck | Polycythemia Vera, Anemia of Inflammation | FPN Internalization Kinetics (Flow Cytometry compatible clones). |
| TMPRSS6 Antisense (Upstream) | Ionis Pharmaceuticals | Iron-refractory anemia | Pathway Cross-talk Validation (HAMP/SLC40A1 double stable cells). |
SLC40A1 Mutation Panel for Hemochromatosis (Type 4 HH)
Key natural mutations in SLC40A1 that confer resistance to hepcidin or alter iron export function must be addressed in drug development. TarMart offers a sequence-verified mutant panel including Y333H (associated with rs1285653301), N144H, A77D, C326Y, and V162del. These mutants allow screening for binding affinity and functional selectivity, ensuring candidate drugs maintain efficacy against clinically relevant variants.